Prospective study on the FDG–PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer
2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron emission tomography/computed tomography (FDG–PET/CT) was carried out before and after neoadjuvant chemoradiotherapy (NCRT) followed by radical surgery for locally advanced rectal cancer (LARC). The aim of this study was to define its predictive and pr...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2011-03, Vol.22 (3), p.650-656 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 656 |
|---|---|
| container_issue | 3 |
| container_start_page | 650 |
| container_title | Annals of oncology |
| container_volume | 22 |
| creator | Martoni, A.A. Di Fabio, F. Pinto, C. Castellucci, P. Pini, S. Ceccarelli, C. Cuicchi, D. Iacopino, B. Di Tullio, P. Giaquinta, S. Tardio, L. Lombardi, R. Fanti, S. Cola, B. |
| description | 2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron emission tomography/computed tomography (FDG–PET/CT) was carried out before and after neoadjuvant chemoradiotherapy (NCRT) followed by radical surgery for locally advanced rectal cancer (LARC). The aim of this study was to define its predictive and prognostic values.
Patients with cT3-T4 N-/+ carcinoma of medium/low rectum received daily 5-fluorouracil–based chemotherapy infusion and radiation therapy on 6-week period followed by surgery 7–8 weeks later. Tumour metabolic activity, expressed as maximum standardised uptake value (SUV-1 = at baseline and SUV-2 = pre-surgery), was calculated in the most active tumour site. Predictive and prognostic values of SUV-1, SUV-2 and Δ-SUV (percentage change of SUV-1 - SUV-2) were analysed towards pathological response (pR) in the surgical specimen and disease recurrence, respectively.
Eighty consecutive patients entered the study. SUV-1, SUV-2 and Δ-SUV appeared singly correlated with pR, but not one of them resulted an independent predictive factor at multivariate analysis. After a median follow-up of 44 months, 13 patients (16.2%) presented local and/or distant recurrence. SUV-2 ≤5 was associated with lower incidence of disease recurrence and resulted prognostic factor at multivariate analysis.
Dual-time FDG–PET/CT in patients with LARC treated with NCRT and radical surgery supplies limited predictive information. However, an optimal metabolic response appears associated with a favourable patient outcome. |
| doi_str_mv | 10.1093/annonc/mdq433 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_853678471</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419386223</els_id><sourcerecordid>853678471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-8619d197db251a765a5226bb18656b1d390d4da187387b6b7042b9d4ff0446913</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhi0EokvhyBX5gjiFtWPHiY9oaQtSJXpYzpFjO11Xib21na32xjvwNH2dPgkTssCJkzXjz-P5_x-ht5R8pESytfI-eL0ezT1n7Bla0UrIoiGcPkcrIktW1BXjZ-hVSneEECFL-RKdlaThNWHlCj3exJD2Vmd3sDjlyRxx8DjvLL78fPX04-fNxXa92eJ9tMYtkPIGynDrQ8pO44MaJpuw83ivsrM-J5yjVdka_ODyDnsblLmbDspnrHd2DFEZB-TyS1T74--Jc1erAacp3tp4xH2IeAjQGeDewGsNAyPsCYyeq_gavejVkOyb03mOvl9ebDdfiutvV183n64LzYnMRSOoNFTWpisrqmpRqaosRdfRRlSio4ZJYrhRtKlZU3eiqwkvO2l43xPOhaTsHH1Y5oLoe5Ca29ElbYdBgbQptU3FRA12zmSxkBo8TdH27T66UcVjS0k7h9UuYbVLWMC_O02eutGav_SfdAB4fwJUAiv6CMJd-scxWVHZcODqhbPgw8HZ2CYNUYBlbrasNcH9Z4VfEYW3fw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>853678471</pqid></control><display><type>article</type><title>Prospective study on the FDG–PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Martoni, A.A. ; Di Fabio, F. ; Pinto, C. ; Castellucci, P. ; Pini, S. ; Ceccarelli, C. ; Cuicchi, D. ; Iacopino, B. ; Di Tullio, P. ; Giaquinta, S. ; Tardio, L. ; Lombardi, R. ; Fanti, S. ; Cola, B.</creator><creatorcontrib>Martoni, A.A. ; Di Fabio, F. ; Pinto, C. ; Castellucci, P. ; Pini, S. ; Ceccarelli, C. ; Cuicchi, D. ; Iacopino, B. ; Di Tullio, P. ; Giaquinta, S. ; Tardio, L. ; Lombardi, R. ; Fanti, S. ; Cola, B.</creatorcontrib><description>2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron emission tomography/computed tomography (FDG–PET/CT) was carried out before and after neoadjuvant chemoradiotherapy (NCRT) followed by radical surgery for locally advanced rectal cancer (LARC). The aim of this study was to define its predictive and prognostic values.
Patients with cT3-T4 N-/+ carcinoma of medium/low rectum received daily 5-fluorouracil–based chemotherapy infusion and radiation therapy on 6-week period followed by surgery 7–8 weeks later. Tumour metabolic activity, expressed as maximum standardised uptake value (SUV-1 = at baseline and SUV-2 = pre-surgery), was calculated in the most active tumour site. Predictive and prognostic values of SUV-1, SUV-2 and Δ-SUV (percentage change of SUV-1 - SUV-2) were analysed towards pathological response (pR) in the surgical specimen and disease recurrence, respectively.
Eighty consecutive patients entered the study. SUV-1, SUV-2 and Δ-SUV appeared singly correlated with pR, but not one of them resulted an independent predictive factor at multivariate analysis. After a median follow-up of 44 months, 13 patients (16.2%) presented local and/or distant recurrence. SUV-2 ≤5 was associated with lower incidence of disease recurrence and resulted prognostic factor at multivariate analysis.
Dual-time FDG–PET/CT in patients with LARC treated with NCRT and radical surgery supplies limited predictive information. However, an optimal metabolic response appears associated with a favourable patient outcome.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdq433</identifier><identifier>PMID: 20847032</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Combined Modality Therapy ; FDG–PET ; Female ; Fluorodeoxyglucose F18 ; Fluorouracil - therapeutic use ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Kaplan-Meier Estimate ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neoadjuvant Therapy ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Pharmacology. Drug treatments ; Positron-Emission Tomography ; predictive and prognostic factor ; preoperative chemoradiation therapy ; Prognosis ; Prospective Studies ; Radiopharmaceuticals ; rectal cancer ; Rectal Neoplasms - diagnostic imaging ; Rectal Neoplasms - pathology ; Rectal Neoplasms - therapy ; ROC Curve ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tomography, X-Ray Computed ; Treatment Outcome ; Tumors</subject><ispartof>Annals of oncology, 2011-03, Vol.22 (3), p.650-656</ispartof><rights>2010 European Society for Medical Oncology</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-8619d197db251a765a5226bb18656b1d390d4da187387b6b7042b9d4ff0446913</citedby><cites>FETCH-LOGICAL-c409t-8619d197db251a765a5226bb18656b1d390d4da187387b6b7042b9d4ff0446913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23951984$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20847032$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martoni, A.A.</creatorcontrib><creatorcontrib>Di Fabio, F.</creatorcontrib><creatorcontrib>Pinto, C.</creatorcontrib><creatorcontrib>Castellucci, P.</creatorcontrib><creatorcontrib>Pini, S.</creatorcontrib><creatorcontrib>Ceccarelli, C.</creatorcontrib><creatorcontrib>Cuicchi, D.</creatorcontrib><creatorcontrib>Iacopino, B.</creatorcontrib><creatorcontrib>Di Tullio, P.</creatorcontrib><creatorcontrib>Giaquinta, S.</creatorcontrib><creatorcontrib>Tardio, L.</creatorcontrib><creatorcontrib>Lombardi, R.</creatorcontrib><creatorcontrib>Fanti, S.</creatorcontrib><creatorcontrib>Cola, B.</creatorcontrib><title>Prospective study on the FDG–PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron emission tomography/computed tomography (FDG–PET/CT) was carried out before and after neoadjuvant chemoradiotherapy (NCRT) followed by radical surgery for locally advanced rectal cancer (LARC). The aim of this study was to define its predictive and prognostic values.
Patients with cT3-T4 N-/+ carcinoma of medium/low rectum received daily 5-fluorouracil–based chemotherapy infusion and radiation therapy on 6-week period followed by surgery 7–8 weeks later. Tumour metabolic activity, expressed as maximum standardised uptake value (SUV-1 = at baseline and SUV-2 = pre-surgery), was calculated in the most active tumour site. Predictive and prognostic values of SUV-1, SUV-2 and Δ-SUV (percentage change of SUV-1 - SUV-2) were analysed towards pathological response (pR) in the surgical specimen and disease recurrence, respectively.
Eighty consecutive patients entered the study. SUV-1, SUV-2 and Δ-SUV appeared singly correlated with pR, but not one of them resulted an independent predictive factor at multivariate analysis. After a median follow-up of 44 months, 13 patients (16.2%) presented local and/or distant recurrence. SUV-2 ≤5 was associated with lower incidence of disease recurrence and resulted prognostic factor at multivariate analysis.
Dual-time FDG–PET/CT in patients with LARC treated with NCRT and radical surgery supplies limited predictive information. However, an optimal metabolic response appears associated with a favourable patient outcome.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Combined Modality Therapy</subject><subject>FDG–PET</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Fluorouracil - therapeutic use</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Pharmacology. Drug treatments</subject><subject>Positron-Emission Tomography</subject><subject>predictive and prognostic factor</subject><subject>preoperative chemoradiation therapy</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Radiopharmaceuticals</subject><subject>rectal cancer</subject><subject>Rectal Neoplasms - diagnostic imaging</subject><subject>Rectal Neoplasms - pathology</subject><subject>Rectal Neoplasms - therapy</subject><subject>ROC Curve</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFu1DAQhi0EokvhyBX5gjiFtWPHiY9oaQtSJXpYzpFjO11Xib21na32xjvwNH2dPgkTssCJkzXjz-P5_x-ht5R8pESytfI-eL0ezT1n7Bla0UrIoiGcPkcrIktW1BXjZ-hVSneEECFL-RKdlaThNWHlCj3exJD2Vmd3sDjlyRxx8DjvLL78fPX04-fNxXa92eJ9tMYtkPIGynDrQ8pO44MaJpuw83ivsrM-J5yjVdka_ODyDnsblLmbDspnrHd2DFEZB-TyS1T74--Jc1erAacp3tp4xH2IeAjQGeDewGsNAyPsCYyeq_gavejVkOyb03mOvl9ebDdfiutvV183n64LzYnMRSOoNFTWpisrqmpRqaosRdfRRlSio4ZJYrhRtKlZU3eiqwkvO2l43xPOhaTsHH1Y5oLoe5Ca29ElbYdBgbQptU3FRA12zmSxkBo8TdH27T66UcVjS0k7h9UuYbVLWMC_O02eutGav_SfdAB4fwJUAiv6CMJd-scxWVHZcODqhbPgw8HZ2CYNUYBlbrasNcH9Z4VfEYW3fw</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Martoni, A.A.</creator><creator>Di Fabio, F.</creator><creator>Pinto, C.</creator><creator>Castellucci, P.</creator><creator>Pini, S.</creator><creator>Ceccarelli, C.</creator><creator>Cuicchi, D.</creator><creator>Iacopino, B.</creator><creator>Di Tullio, P.</creator><creator>Giaquinta, S.</creator><creator>Tardio, L.</creator><creator>Lombardi, R.</creator><creator>Fanti, S.</creator><creator>Cola, B.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110301</creationdate><title>Prospective study on the FDG–PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer</title><author>Martoni, A.A. ; Di Fabio, F. ; Pinto, C. ; Castellucci, P. ; Pini, S. ; Ceccarelli, C. ; Cuicchi, D. ; Iacopino, B. ; Di Tullio, P. ; Giaquinta, S. ; Tardio, L. ; Lombardi, R. ; Fanti, S. ; Cola, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-8619d197db251a765a5226bb18656b1d390d4da187387b6b7042b9d4ff0446913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Combined Modality Therapy</topic><topic>FDG–PET</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Fluorouracil - therapeutic use</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Pharmacology. Drug treatments</topic><topic>Positron-Emission Tomography</topic><topic>predictive and prognostic factor</topic><topic>preoperative chemoradiation therapy</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Radiopharmaceuticals</topic><topic>rectal cancer</topic><topic>Rectal Neoplasms - diagnostic imaging</topic><topic>Rectal Neoplasms - pathology</topic><topic>Rectal Neoplasms - therapy</topic><topic>ROC Curve</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martoni, A.A.</creatorcontrib><creatorcontrib>Di Fabio, F.</creatorcontrib><creatorcontrib>Pinto, C.</creatorcontrib><creatorcontrib>Castellucci, P.</creatorcontrib><creatorcontrib>Pini, S.</creatorcontrib><creatorcontrib>Ceccarelli, C.</creatorcontrib><creatorcontrib>Cuicchi, D.</creatorcontrib><creatorcontrib>Iacopino, B.</creatorcontrib><creatorcontrib>Di Tullio, P.</creatorcontrib><creatorcontrib>Giaquinta, S.</creatorcontrib><creatorcontrib>Tardio, L.</creatorcontrib><creatorcontrib>Lombardi, R.</creatorcontrib><creatorcontrib>Fanti, S.</creatorcontrib><creatorcontrib>Cola, B.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martoni, A.A.</au><au>Di Fabio, F.</au><au>Pinto, C.</au><au>Castellucci, P.</au><au>Pini, S.</au><au>Ceccarelli, C.</au><au>Cuicchi, D.</au><au>Iacopino, B.</au><au>Di Tullio, P.</au><au>Giaquinta, S.</au><au>Tardio, L.</au><au>Lombardi, R.</au><au>Fanti, S.</au><au>Cola, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospective study on the FDG–PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>22</volume><issue>3</issue><spage>650</spage><epage>656</epage><pages>650-656</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron emission tomography/computed tomography (FDG–PET/CT) was carried out before and after neoadjuvant chemoradiotherapy (NCRT) followed by radical surgery for locally advanced rectal cancer (LARC). The aim of this study was to define its predictive and prognostic values.
Patients with cT3-T4 N-/+ carcinoma of medium/low rectum received daily 5-fluorouracil–based chemotherapy infusion and radiation therapy on 6-week period followed by surgery 7–8 weeks later. Tumour metabolic activity, expressed as maximum standardised uptake value (SUV-1 = at baseline and SUV-2 = pre-surgery), was calculated in the most active tumour site. Predictive and prognostic values of SUV-1, SUV-2 and Δ-SUV (percentage change of SUV-1 - SUV-2) were analysed towards pathological response (pR) in the surgical specimen and disease recurrence, respectively.
Eighty consecutive patients entered the study. SUV-1, SUV-2 and Δ-SUV appeared singly correlated with pR, but not one of them resulted an independent predictive factor at multivariate analysis. After a median follow-up of 44 months, 13 patients (16.2%) presented local and/or distant recurrence. SUV-2 ≤5 was associated with lower incidence of disease recurrence and resulted prognostic factor at multivariate analysis.
Dual-time FDG–PET/CT in patients with LARC treated with NCRT and radical surgery supplies limited predictive information. However, an optimal metabolic response appears associated with a favourable patient outcome.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>20847032</pmid><doi>10.1093/annonc/mdq433</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2011-03, Vol.22 (3), p.650-656 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_853678471 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Combined Modality Therapy FDG–PET Female Fluorodeoxyglucose F18 Fluorouracil - therapeutic use Gastroenterology. Liver. Pancreas. Abdomen Humans Kaplan-Meier Estimate Male Medical sciences Middle Aged Multivariate Analysis Neoadjuvant Therapy Neoplasm Recurrence, Local Neoplasm Staging Pharmacology. Drug treatments Positron-Emission Tomography predictive and prognostic factor preoperative chemoradiation therapy Prognosis Prospective Studies Radiopharmaceuticals rectal cancer Rectal Neoplasms - diagnostic imaging Rectal Neoplasms - pathology Rectal Neoplasms - therapy ROC Curve Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tomography, X-Ray Computed Treatment Outcome Tumors |
| title | Prospective study on the FDG–PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T18%3A53%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospective%20study%20on%20the%20FDG%E2%80%93PET/CT%20predictive%20and%20prognostic%20values%20in%20patients%20treated%20with%20neoadjuvant%20chemoradiation%20therapy%20and%20radical%20surgery%20for%20locally%20advanced%20rectal%20cancer&rft.jtitle=Annals%20of%20oncology&rft.au=Martoni,%20A.A.&rft.date=2011-03-01&rft.volume=22&rft.issue=3&rft.spage=650&rft.epage=656&rft.pages=650-656&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdq433&rft_dat=%3Cproquest_cross%3E853678471%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=853678471&rft_id=info:pmid/20847032&rft_els_id=S0923753419386223&rfr_iscdi=true |